脓毒症与脓毒性休克患者的辅助免疫治疗:23位多学科专家共识
该共识由多学科专家组采用改良RAND/UCLA适宜性方法制定,先界定脓毒症与脓毒性休克的临床表型及关注的辅助治疗与结局,再经系统文献综述评估各治疗在各表型中的适宜性。共识识别出两种临床表型:压倒性休克患者与免疫麻痹患者;考虑6类最常用且有前景的辅助治疗:糖皮质激素、血液净化、免疫球蛋白、粒细胞/单核细胞集落刺激因子及特异性免疫治疗(即干扰素-γ、IL-7和抗PD1)。在25个临床问题中70%达成一致。作者指出临床证据仍缺乏但辅助治疗在脓毒症中常被使用,故提供结构化共识以指导临床实践。
要点
- 共识识别两种临床表型:压倒性休克患者与免疫麻痹患者
- 考虑6类最常用且有前景的辅助治疗:糖皮质激素、血液净化、免疫球蛋白、粒细胞/单核细胞集落刺激因子、特异性免疫治疗(干扰素-γ、IL-7、抗PD1)
- 采用改良RAND/UCLA适宜性方法,经系统文献综述后评估各治疗对各表型的适宜性
- 25个临床问题中70%达成一致
- 作者指出临床证据缺乏,但辅助治疗在脓毒症中常被使用
适用人群与场景
- 脓毒症与脓毒性休克患者
- 共识界定两种临床表型:压倒性休克患者与免疫麻痹患者
处置流程与药物剂量
- 考虑的6类辅助治疗:糖皮质激素、血液净化、免疫球蛋白、粒细胞/单核细胞集落刺激因子、特异性免疫治疗(即干扰素-γ、IL-7和抗PD1)
研究设计与关键结果
- 制定机构:多学科专家组(23位专家)
- 方法:先界定临床表型、治疗与结局,经广泛系统文献综述后用改良RAND/UCLA适宜性方法确定各治疗对各临床表型的适宜性
- 识别两种临床表型:压倒性休克患者与免疫麻痹患者
- 考虑6类最常用且有前景的辅助治疗:糖皮质激素、血液净化、免疫球蛋白、粒细胞/单核细胞集落刺激因子、特异性免疫治疗(即干扰素-γ、IL-7和抗PD1)
- 25个临床问题中70%达成一致
证据类型、等级与局限
- 证据类型:多学科专家共识(指南/共识)
- 证据等级:采用改良RAND/UCLA适宜性方法达成共识
- 局限:原文未报告局限性
对床旁实践的改变
- 作者认为,尽管临床证据缺乏,辅助治疗常被用于脓毒症治疗,专家组就这些治疗在临床实践中的适当使用提供了结构化共识
指南或共识出处
- 脓毒症与脓毒性休克患者的辅助免疫治疗:23位多学科专家共识(J Anesth Analg Crit Care)
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: In the last decades, several adjunctive treatments have been proposed to reduce mortality in septic shock patients. Unfortunately, mortality due to sepsis and septic shock remains elevated and NO trials evaluating adjunctive therapies were able to demonstrate any clear benefit. In light of the lack of evidence and conflicting results from previous studies, in this multidisciplinary consensus, the authors considered the rational, recent investigations and potential clinical benefits of targeted adjunctive therapies.
METHODS: A panel of multidisciplinary experts defined clinical phenotypes, treatments and outcomes of greater interest in the field of adjunctive therapies for sepsis and septic shock. After an extensive systematic literature review, the appropriateness of each treatment for each clinical phenotype was determined using the modified RAND/UCLA appropriateness method.
RESULTS: The consensus identified two distinct clinical phenotypes: patients with overwhelming shock and patients with immune paralysis. Six different adjunctive treatments were considered the most frequently used and promising: (i) corticosteroids, (ii) blood purification, (iii) immunoglobulins, (iv) granulocyte/monocyte colony-stimulating factor and (v) specific immune therapy (i.e. interferon-gamma, IL7 and AntiPD1). Agreement was achieved in 70% of the 25 clinical questions.
CONCLUSIONS: Although clinical evidence is lacking, adjunctive therapies are often employed in the treatment of sepsis. To address this gap in knowledge, a panel of national experts has provided a structured consensus on the appropriate use of these treatments in clinical practice.
参考来源
- Girardis M, Coloretti I, Antonelli M, et al. Adjunctive immunotherapeutic agents in patients with sepsis and septic shock: a multidisciplinary consensus of 23. J Anesth Analg Crit Care. 2024. PMID: 38689337. doi:10.1186/s44158-024-00165-3
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。